Enveda

Daniel Wee, Chief eXecution Officer at Enveda, sits down with Nasdaq’s Kristina Ayanian to discuss why the company is focused on nature’s chemistry, how AI is transforming drug discovery, and the strategies that have enabled Enveda to raise capital in a challenging biotech market. Wee also shares insights on the biggest industry challenges and how Enveda is meeting them head-on.